Human immune healthHuman research complete
T‑Booster
- 18-ingredient immune-health formulation
- Four years of R&D development
- Two controlled studies · 260 adults
SCIENTIFIC FOUNDER
Dr Md Arif Sheikh
Drug discoverer, cancer scientist & venture builder
Founder and CEO of AVIX Pharmaceuticals, translating more than 20 years of molecular, structural and cancer research into three science-led ventures.
Founder profile · Dr Md Arif Sheikh
From scientistto entrepreneur.
Dr Md Arif Sheikh spent years in academic and drug-discovery research interrogating biology at molecular level. A harder question increasingly shaped his work: how can science leave the laboratory and become useful in everyday life? He founded AVIX Pharmaceuticals Limited in the UK in 2018. Today that decision connects three ventures across human immune health, animal health and functional hydration.
THE ENTREPRENEURIAL JOURNEY
01
Scientific foundationAcademic & drug-discovery research
02
Founder decisionTranslate science into useful products
03
2018 · United KingdomAVIX Pharmaceuticals Limited
T‑BoosterHuman immune health
Green AntibioticsAnimal health & AMR
AVIX WaterFunctional hydration
2018AVIX FOUNDED IN THE UK
3 venturesONE FOUNDER JOURNEY
20+ yearsSCIENTIFIC EXPERIENCE
260 adultsT‑BOOSTER HUMAN RESEARCH
01 · The turning point
Leaving academiato build with science.
Academic science gave Dr Sheikh the discipline to ask difficult questions, challenge assumptions and understand biological systems at molecular level. Over time, however, the question that mattered most became what happened after discovery: could scientific thinking survive the practical demands of formulation, testing, manufacturing and ultimately become useful in the real world?
That question changed the direction of his career. In 2018 he founded AVIX Pharmaceuticals Limited in the United Kingdom — not to step away from science, but to carry it further, from rationale into specified products and from ideas into evidence-generating programmes.
AVIX was conceived as more than a home for one product. The founder thesis was to build a repeatable capability: identify an important problem, design a reasoned solution, test what matters, keep the limits visible and create a credible pathway towards manufacture, partnership and market.
“I left academia because I wanted science to make a difference beyond the laboratory.”
02 · Building AVIX
Three ventures emergedfrom one founder conviction.
The problems are very different, but the founder logic is deliberate: start with a real need, let science shape the solution, generate the next proof and advance only as far as the evidence justifies.
Animal health & AMRLaboratory evidence
Green Antibiotics
- Plant-derived antimicrobial combinations
- 41 combinations systematically screened
- Seven leads advanced for development
Functional hydrationManufacturing route
AVIX Water
- Four-product functional-water platform
- Defined mineral + functional composition
- Verification-led manufacturing pathway
Three categories, three evidence stages and three different routes to market — connected by one discipline: define the problem, design precisely, test honestly and advance deliberately.
Explore the AVIX portfolio →03 · Founder method
Science sets the direction.Execution builds the venture.
AVIX is not built on the idea that science alone creates value. Value appears when scientific discipline survives the work of specification, evidence, manufacturing, partnership and market entry — without allowing the story to outrun the data.
Choose the problem
Start with a problem worth solving.
- Understand the unmet need
- Define success before product
- Avoid product-first assumptions
Specify the solution
Turn rationale into a testable solution.
- Specify the formulation
- Make assumptions measurable
- Anchor choices in rationale
Generate evidence
Test what matters with clear evidence.
- Use meaningful comparators
- Measure critical outcomes
- Keep limitations visible
Earn the next gate
Progress only when evidence supports it.
- Prepare manufacturing and IP
- Align claims with evidence
- Earn the next milestone
04 · T‑Booster as proof of execution
T‑Booster has travelledfurthest towards market.
Among the three AVIX ventures, T‑Booster is the clearest demonstration of translation to date: a biological rationale became an 18-ingredient formulation, a UK GMP manufacturing route, two controlled human studies and a programme now moving through final analysis, publication, IP and launch preparation.
For an investor or strategic partner, the signal is not a single result. It is continuity of execution — Dr Sheikh has remained involved from scientific rationale and formulation through team building, research execution and commercial preparation.